| **Author, year** | **Intervention, n** | **Demographics** | **Age, in years** | **Disease characteristics** | **Disease activity index** | **Medications taken during study, %** | **Medications taken BEFORE study, %** | **Medications taken FOR INDUCTION, %** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Alemzadeh, 2002200 | Placebo, 108 | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Alemzadeh, 2002200 | Corticosteroid, 27 | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Beaugerie, 2009130 | Never user thiopurine, 10810  Dose: NA | Male, %: 47  Race NR  Smoking NR  CD, %: 48 | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 42.3 | Severity NR  Location, %  Ileal: 33.3  Colonic: 30.5  Perianal: 7.3  Behavior NR  CRP NR | Disease activity index NR | TNF-alpha inhibitors: 0.6  Methotrexate: 0.4  Cyclosporin, mycophenolate mofetil, or cyclophosamide: 0.6 | TNF-alpha inhibitors: 0.9  Methotrexate: 0.6 | NR |
| Beaugerie, 2009130 | Thiopurine, 8676  Dose: NR | Male, %: 43  Race NR  Smoking NR  CD, %: 76.1 | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location, %  Ileal: 53.3  Colonic: 59.3  Perianal: 24.5  Behavior NR  CRP NR | Disease activity index NR | TNF-alpha inhibitors: 10  Methotrexate: 7.5  Cyclosporin, mycophenolate mofetil, or cyclophosamide: 1.6 | TNF-alpha inhibitors: 21.3  Methotrexate: 15.3 | NR |
| Candy, 199553 | Azathioprine + Prednisolone, 33  Route: Oral + Oral  Dose: 2.5 mg/kg every day + 1 mg/kg every day | Male, %: 21  Race NR  Smoking, %  Smoker, 67  CD NR | Age at diagnosis NR  Disease duration  Median: 2.6  Min: 0.1  Max: 19.3  Age at enrollment  Median: 33.9  Min: 15  Max: 60 | Severity, %  Severe disease: 52  Location, %  Ileal: 24.2  Ileo-colonic: 60.6  Colonic: 15.2  Behavior NR  CRP  Median: 5.4  Min: 2.9  Max: 7.3 | CDAI  Median: 301  Min: 264  Max: 358 | Corticosteroids: 100  Thiopurines: 100 | corticosteroids in previous 6-12 mo: 67  no previous corticosteroids: 15  : 15 | NR |
| Candy, 199553 | Placebo + Prednisolone, 30  Route: Oral + Oral  Dose: NA + 1 mg/kg every day | Male, %: 37  Race NR  Smoking, %  Smoker, 67  CD NR | Age at diagnosis NR  Disease duration  Median: 3.7  Min: 0.1  Max: 18.7  Age at enrollment  Median: 31.8  Min: 21  Max: 62 | Severity, %  Severe disease: 43  Location, %  Ileal: 20  Ileo-colonic: 63.3  Colonic: 16.7  Behavior NR  CRP  Median: 3.9  Min: 2.8  Max: 5.3 | CDAI  Median: 282  Min: 240  Max: 356 | Corticosteroids: 100 | Corticosteroids  corticosteroids in the last 6 months: 63  no previous corticosteroids: 7  : 7 | NR |
| Cezard, 2009194 | Placebo, 62 | Male, %: 58  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration  Mean: 0.6  Age at enrollment  Mean: 11.6 | Severity NR  Location, %  Ileal: 11  Ileo-colonic: 69  Colonic: 19  Perianal: 31  Behavior NR  CRP NR | HBI  Mean: 0.9 | NR | NR | NR |
| Cezard, 2009194 | Mesalamine (Pentasa), 60  Dose: 50 mg/kg every day | Male, %: 62  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration  Mean: 1.1  Age at enrollment  Mean: 12 | Severity NR  Location, %  Ileal: 13  Ileo-colonic: 68  Colonic: 18  Perianal: 33  Behavior NR  CRP NR | HBI  Mean: 0.7 | NR | NR | NR |
| Crombe, 2011226  EPIMAD | Infliximab + immunomodulator, 103 Route: Unknown + Unknown Dose: 5 mg/kg every 8 weeks + NR | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | 5ASA  Corticosteroids | NR | NR |
| Crombe, 2011226  EPIMAD | Infliximab + no IMM, 17 Route: Unknown Dose: NA | Gender NR  Race NR  Smoking NR  CD, %: 100 | NR | NR | Disease activity index NR | 5ASA  Corticosteroids | NR | NR |
| de Vries, 2008227 | Infliximab + Immunomodulator, 93 | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | Corticosteroids | NR | NR |
| de Vries, 2008227 | Infliximab + No corticosteroids, 45 | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | Immunomodulators | NR | NR |
| de Vries, 2008227 | Infliximab + No immunomodulator, 54 | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | Corticosteroids | NR | NR |
| de Vries, 2008227 | Infliximab + Corticosteroid, 102 | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | Immunomodulators | NR | NR |
| D'Haens, 200848 | Budesonide + (6)-Methylprednisolone, 64  Route: Oral + Oral  Dose: 9 mg every days + 32 mg every day | Male, %: 42.2  Race, %  W: 95.3  Smoking, %  Current smoker, 35.9  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 28.7 | Severity NR  Location, %  Ileo-colonic: 43.8  Colonic: 32.8  Behavior NR  CRP  Median: 25 | CDAI  Mean: 306  IBDQ  Mean: 136 | TNF-alpha inhibitors  Corticosteroids  Methotrexate  Thiopurines  Budesonide | 5ASA: 3.1 | NR |
| D'Haens, 200848 | Infliximab + Azathioprine, 65  Route: IV + Oral  Dose: 5 mg/kg + 2-2.5 mg/kg | Male, %: 33.8  Race, %  W: 98.5  Smoking, %  Current smoker, 43.1  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 30 | Severity NR  Location, %  Ileo-colonic: 47.7  Colonic: 30.8  Behavior NR  CRP  Median: 19 | CDAI  Mean: 330  IBDQ  Mean: 122 | TNF-alpha inhibitors: 100  Methotrexate  Azathioprine: 100  Methylprednisolone | 5ASA: 4.6 | NR |
| Escher, 2004190 | Prednisolone, 26  Dose: 1 mg/kg every day | Male, %: 69.2  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration  Mean: 0.8  Age at enrollment  Mean: 13 | Severity NR  Location, %  Ileal: 26.9  Ileo-colonic: 65.4  Colonic: 3.8  Behavior NR  CRP NR | CDAI  Mean: 268  PCDAI  Mean: 45 | NR | NR | NR |
| Escher, 2004190 | Budesonide, 22  Dose: 9 mg every day | Male, %: 31.8  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration  Mean: 0.6  Age at enrollment  Mean: 13 | Severity NR  Location, %  Ileal: 59.1  Ileo-colonic: 31.8  Colonic: 9.1  Behavior NR  CRP NR | CDAI  Mean: 239  PCDAI  Mean: 39 | NR | NR | NR |
| Griffiths, 1993221 | Mesalamine (Pentasa), 7  Route: Oral  Dose: 50 mg/kg every day | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | CDAI  Mean: 188.3  HBI  Mean: 3.71 | NR | NR | NR |
| Griffiths, 1993221 | Placebo, 6  Route: Oral  Dose: NA every day | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | CDAI  Mean: 182.5  HBI  Mean: 3.5 | NR | NR | NR |
| Issenman, 1993196 | Discontinued corticosteroids, 8 | Male, %: 100  Race NR  Smoking NR  CD, %: 212.5 | Age at diagnosis  Mean: 13.2  Disease duration NR  Age at enrollment  Mean: 13.2 | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Issenman, 1993196 | Prednisone, 9  Route: Oral  Dose: 2 mg/kg every days | Male, %: 100  Race NR  Smoking NR  CD NR | Age at diagnosis  Mean: 14.5  Disease duration NR  Age at enrollment  Mean: 14.5 | Severity NR  Location NR  Behavior NR  CRP NR | CDAI  Mean: 64.1 | Corticosteroids: 100 | 5ASA | NR |
| Lees, 2009145 | Adalimumab, 30 | Male, %: 36.7  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Median: 32.3 | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Azathioprine, 51  Route: IV  Dose: NR + NR | Gender NR  Race NR  Smoking NR  CD, %: 100 | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Corticosteroid, 32  Route: IV + Unknown  Dose: NR + NR | Gender NR  Race NR  Smoking NR  CD, %: 100 | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Azathioprine/6-MP/methotrexate + corticosteroids, 55  Route: IV + Unknown  Dose: NR + NR | Gender NR  Race NR  Smoking NR  CD, %: 100 | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Never user concomitant azathioprine/6-MP/methotrexate/corticosteroids, 19  Route: IV  Dose: NR | Gender NR  Race NR  Smoking NR  CD, %: 100 | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Levine, 2002198 | Budesonide, 62  Dose: 9 mg every day | Male, %: 59.7  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 14.1 | Severity NR  Location NR  Behavior NR  CRP NR | PCDAI  Mean: 25.8 | NR | immunomodulators: 29 | NR |
| Levine, 2002198 | Prednisone, 58  Dose: 40 mg every day | Male, %: 60.3  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 13.7 | Severity NR  Location NR  Behavior NR  CRP NR | PCDAI  Mean: 29.6 | NR | immunomodulators: 20.6 | NR |
| Levine, 2003191 | Prednisone + Mesalamine, 14  Dose: 40 mg every day + 3-4 g every day | Male, %: 50  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 14.15 | Severity NR  Location NR  Behavior NR  CRP NR | PCDAI  Mean: 28.9 | NR | NR | NR |
| Levine, 2003191 | Budesonide + Mesalamine, 19  Dose: 3 mg every 8 hours + 3-4 g every day | Male, %: 68.4  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 13.8 | Severity NR  Location NR  Behavior NR  CRP NR | PCDAI  Mean: 29.3 | NR | NR | NR |
| Malik, 2011229  Royal Hospital Sick Children | Infliximab + no steroid, 13 Route: IV Dose: 5 mg/kg every 2 weeks | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Methotrexate | NR | NR |
| Malik, 2011229  Royal Hospital Sick Children | Infliximab + Methotrexate, 21 | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Corticosteroids | NR | NR |
| Malik, 2011229  Royal Hospital Sick Children | Infliximab + no MTX, 7 | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Corticosteroids | NR | NR |
| Malik, 2011229  Royal Hospital Sick Children | Infliximab + steroid, 15 | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Methotrexate | NR | NR |
| Markowitz, 2000192 | 6-MP + Prednisone, 27  Dose: 1.5 mg/kg every day + 40 mg every day | Male, %: 55.6  Race, %  W: 93  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 13 | Severity NR  Location, %  Ileal: 14.8  Ileo-colonic: 70.4  Colonic: 14.8  Behavior NR  CRP NR | PCDAI  Mean: 46.7  HBI  Mean: 7.7  partial HB  Mean: 6.6 | NR | NR | NR |
| Markowitz, 2000192 | Placebo + Prednisone, 28  Dose: 40 mg every day | Male, %: 64.3  Race, %  W: 93  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment  Mean: 13.4 | Severity NR  Location, %  Ileal: 3.6  Ileo-colonic: 78.6  Colonic: 17.9  Behavior NR  CRP NR | PCDAI  Mean: 44.7  HBI  Mean: 7.4  partial HB  Mean: 6.5 | NR | NR | NR |
| Mate-Jimenez, 200052 | 6-MP, 16  Route: Oral  Dose: 1.5 mg/kg every day | Gender NR  Race NR  Smoking, %  Smoker, 75  CD NR | Age at diagnosis NR  Disease duration  Mean: 4.5  Age at enrollment NR | Severity NR  Location, %  Colonic: 37.5  Perianal: 25  Behavior NR  CRP NR | CDAI  Mean: 191 | Corticosteroids: 100 | NR | NR |
| Mate-Jimenez, 200052 | Methotrexate, 15  Route: Oral  Dose: 15 mg every 1 week | Gender NR  Race NR  Smoking, %  Smoker, 66.7  CD NR | Age at diagnosis NR  Disease duration  Mean: 4.3  Age at enrollment NR | Severity NR  Location, %  Colonic: 40  Perianal: 20  Behavior NR  CRP NR | CDAI  Mean: 200 | Corticosteroids: 100 | NR | NR |
| Mate-Jimenez, 200052 | 5-ASA, 7  Route: Oral  Dose: 3 g every day | Gender NR  Race NR  Smoking, %  Smoker, 85.7  CD NR | Age at diagnosis NR  Disease duration  Mean: 3.5  Age at enrollment NR | Severity NR  Location, %  Colonic: 14.3  Perianal: 14.3  Behavior NR  CRP NR | CDAI  Mean: 215 | Corticosteroids: 100 | NR | NR |
| Present, 198060 | 6-MP  Route: Unknown  Dose: 1.5 mg/kg every 24 hours | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Present, 198060 | Placebo  Route: Oral  Dose: NA | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Rhodes, 197161 | Azathioprine, 16  Route: Oral  Dose: 4 mg/kg every 24 hours | Male, %: 75  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration  Min: 1  Max: 14  Age at enrollment  Min: 14  Max: 69 | Severity NR  Location, %  Ileal: 50  Ileo-colonic: 37.5  Colonic: 12.5  Behavior NR  CRP NR | Disease activity index NR | Sulfasalazine: 18.8  Prednisolone: 18.8 | NR | NR |
| Rhodes, 197161 | Placebo, 16  Route: Oral  Dose: NA | Male, %: 75  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration  Min: 1  Max: 16  Age at enrollment  Min: 14  Max: 69 | Severity NR  Location, %  Ileal: 50  Ileo-colonic: 37.5  Colonic: 12.5  Behavior NR  CRP NR | Disease activity index NR | Corticosteroids: 18.8  Sulfasalazine: 18.8 | NR | NR |
| Russell, 2011236 | Adalimumab + no IMM (Thio or MTX) +/- steroid, 24 Route: Unknown + Unknown Dose: 40 mg every 15 days + NR | Gender NR  Race NR  Smoking NR  CD, %: 283.3 | NR | NR | Disease activity index NR | Corticosteroids | TNF-alpha inhibitors  Corticosteroids  Methotrexate  Thiopurines  Immunomodulators | NR |
| Russell, 2011236 | Adalimumab + IMM (Thio or MTX) +/- steroid, 46 Route: Unknown + Unknown Dose: NR | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Corticosteroids | TNF-alpha inhibitors  Corticosteroids  Methotrexate  Thiopurines  Immunomodulators | NR |
| Saha, 1998197 | Placebo | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Saha, 1998197 | Prednisone | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Infliximab | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Placebo | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Corticosteroid | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Methotrexate | Gender NR  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration NR  Age at enrollment NR | Severity NR  Location NR  Behavior NR  CRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010237  CHOP | Corticosteroid | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Corticosteroids: 100 | NR | NR | 30 |
| Thayu, 2010237  CHOP | No infliximab | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | NR | NR | NR | 30 |
| Thayu, 2010237  CHOP | No MTX | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | NR | NR | NR | 30 |
| Thayu, 2010237  CHOP | Infliximab | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | infliximab: 100 | NR | NR | 30 |
| Thayu, 2010237  CHOP | Methotrexate | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | Methotrexate: 100 | NR | NR | 30 |
| Thayu, 2010237  CHOP | No steroids | Gender NR  Race NR  Smoking NR  CD NR | NR | NR | Disease activity index NR | NR | NR | NR | 30 |
| Thomson, 1990224 | Placebo, 105 Route: Oral Dose: NA every 8 hours | Male, %: 45.7  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration Mean: 5.3  Age at enrollment Mean: 37.4 | NR | CDAI Mean: 60.1 | NR | sulphasalazine: 16.2 | NR | 2 |
| Thomson, 1990224 | 5-ASA, 101 Dose: 500 mg every 8 hours | Male, %: 42.6  Race NR  Smoking NR  CD NR | Age at diagnosis NR  Disease duration Mean: 6  Age at enrollment Mean: 34.1 | NR | CDAI Mean: 51.8 | NR | sulphasalazine: 15.8 | NR | 2 |
| Van Assche, 200889 | Infliximab, 40  Route: IV  Dose: 5 mg/kg every 8 weeks | Male, %: 47.5  Race NR  Smoking, %  Smoker, 47.5  CD NR | Age at diagnosis NR  Disease duration  Median: 9  Min: 2  Max: 25  Age at enrollment  Mean: 35.4 | Severity NR  Location, %  Colonic: 12.5  Behavior NR  CRP  Median: 3.2 | CDAI  Mean: 138.1 | TNF-alpha inhibitors: 100 | TNF-alpha inhibitors: 100  Methotrexate  Thiopurines | NR |
| Van Assche, 200889 | Infliximab + Immunomodulator, 40  Route: IV + Oral  Dose: 5 mg/kg every 8 weeks + see below | Male, %: 42.5  Race NR  Smoking, %  Smoker, 45  CD NR | Age at diagnosis NR  Disease duration  Median: 9  Min: 1  Max: 36  Age at enrollment  Mean: 35.6 | Severity NR  Location, %  Colonic: 32.5  Behavior NR  CRP  Median: 3.4 | CDAI  Mean: 137.6 | TNF-alpha inhibitors: 100  Methotrexate  Thiopurines | TNF-alpha inhibitors: 100  Methotrexate  Thiopurines | NR |

Abbreviations: 5ASA = 5-aminosalicylic acid; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; CRP = C-reactive protein; g = gram; HBI = Harvey-Bradshaw Index; Max. = maximum; Min. = minimum; NA = not applicable; NR = not reported; TNF = tumor necrosis factor